Paper Details

  1. Home
  2. Paper Details

Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies.

Author: ChandeNilesh, CiprianoLauren E, FeaganBrian G, GregorJames C, GuizzettiLeonardo, JairathVipul, MaChristopher, NguyenTran M, ParkerClaire E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Approximately 80% of patients with ulcerative colitis entering clinical trials continue to use aminosalicylates. Further research is needed to determine the benefits and harms of continuing vs stopping aminosalicylates during escalating therapy.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Aminosalicylates are the most frequently prescribed treatment for ulcerative colitis (UC). In the absence of empirical evidence, clinicians are uncertain whether to continue aminosalicylates in patients with UC after escalating therapy. AIMS: To quantify concomitant aminosalicylate use ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/apt.15090

データ提供：米国国立医学図書館（NLM）

Ulcerative Colitis: A Long and Winding Road

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that can be a challenging and unpredictable journey, like crossing a vast and unforgiving desert. This study delves into the complexities of UC treatment, examining the prevalence and cost of continued aminosalicylate use in patients who have escalated to immunosuppressive and biological therapies.

Navigating the Treatment Desert

The study found that a significant proportion of UC patients, approximately 80%, continue to use aminosalicylates even after escalating therapy. This finding suggests a need for further research to determine the optimal course of treatment for these patients. It is crucial to navigate the treatment desert with a clear understanding of the benefits and risks associated with different therapies.

Finding the Right Path

This research provides a valuable roadmap for clinicians managing UC patients who have escalated therapy. The study highlights the need for a randomized controlled trial to evaluate the benefits and harms of continuing versus stopping aminosalicylates in this population. This research is essential for finding the right path through the treatment desert, ensuring the best possible outcomes for UC patients.

Dr.Camel's Conclusion

This study explores the prevalence and cost of continued aminosalicylate use in ulcerative colitis patients who have escalated to more potent therapies. The findings suggest that further research is needed to determine the optimal course of treatment for these patients. This study provides a valuable contribution to the ongoing quest for effective and personalized management strategies for UC.

Date :
  1. Date Completed 2020-01-06
  2. Date Revised 2020-01-06
Further Info :

Pubmed ID

30569460

DOI: Digital Object Identifier

10.1111/apt.15090

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.